Cottler L B, Shillington A M, Compton W M, Mager D, Spitznagel E L
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110.
Drug Alcohol Depend. 1993 Sep;33(2):97-104. doi: 10.1016/0376-8716(93)90051-q.
The proposed DSM-IV criteria for substance use disorders have included, as an option, a subtyping for physiologic dependence, characterized by either tolerance or withdrawal. Even if this option is not chosen at this stage of system revision, this weighting scheme justifies wider surveillance of these symptoms, especially for the more newly described cocaine dependence disorder. Wider surveillance of withdrawal is possible with the CIDI Substance Abuse Module (SAM), a WHO/ADAMHA diagnostic interview which covers criteria of substance use disorders according to the DSM-III, III-R, ICD-10 and proposed DSM-IV systems. To aid in this effort, we used the SAM, which includes a master list of all symptoms (n = 16) in the DSM manuals related to withdrawal from any substance to assess withdrawal symptoms from all substances. In this study, we hypothesized that the persons who used opiates with cocaine might misattribute their symptoms to cocaine; thus, we compared the responses of persons who used cocaine and opiates (opiate users) with the responses of persons who used cocaine without opiates (non-opiate users). Data from two St. Louis studies were combined for these analyses, users not in treatment or newly enrolled to drug-free or methadone treatment from a NIDA demonstration project and users selected for the St. Louis DSM-IV Field Trial. Of the 196 persons included from the field trial, 80% reported lifetime cocaine use compared with 91% of the 412 persons from the demonstration project. The symptoms mentioned in the diagnostic manuals were among the most frequently endorsed by both cocaine use groups.(ABSTRACT TRUNCATED AT 250 WORDS)
《精神疾病诊断与统计手册》第四版(DSM-IV)中提出的物质使用障碍标准,作为一种选择,包括对生理依赖进行亚型分类,其特征为耐受性或戒断反应。即使在系统修订的现阶段未选择此选项,这种加权方案也证明对这些症状进行更广泛监测是合理的,特别是对于新描述的可卡因依赖障碍。使用世界卫生组织/美国酒精、药物滥用和精神健康管理局(WHO/ADAMHA)的诊断访谈工具——复合国际诊断访谈中的物质滥用模块(CIDI SAM),可以更广泛地监测戒断反应,该模块涵盖了根据《精神疾病诊断与统计手册》第三版、第三版修订本、国际疾病分类第十版(ICD-10)以及提议的DSM-IV系统制定的物质使用障碍标准。为协助此项工作,我们使用了CIDI SAM,它包含了DSM手册中与任何物质戒断相关的所有症状(n = 16)的主列表,以评估所有物质的戒断症状。在本研究中,我们假设同时使用阿片类药物和可卡因的人可能会将他们的症状归因于可卡因;因此,我们将使用可卡因和阿片类药物的人(阿片类药物使用者)的回答与仅使用可卡因的人(非阿片类药物使用者)的回答进行了比较。为进行这些分析,我们合并了来自圣路易斯两项研究的数据,这些使用者来自美国国立药物滥用研究所(NIDA)示范项目中未接受治疗或新加入无毒品或美沙酮治疗的人群,以及被选入圣路易斯DSM-IV现场试验的人群。在现场试验纳入的196人中,80%报告有终生可卡因使用史,相比之下,示范项目的412人中有91%有此报告。诊断手册中提到的症状是两个可卡因使用组最常认可的症状之一。(摘要截选至250字)